Drug Profile
AAV9-Follistatin
Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Nationwide Children's Hospital
- Developer Milo Biotechnology
- Class Gene therapies
- Mechanism of Action Activin inhibitors; Follistatin stimulants; Gene transference; Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Muscular atrophy
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Muscular atrophy in USA (unspecified route) before August 2023
- 28 Dec 2019 No recent reports of development identified for preclinical development in Muscle-wasting in USA
- 20 Nov 2015 Preclinical trials in Muscular atrophy in USA (unspecified route) before November 2015